MedTrace Logo

Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization

NCT03013647 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-01-06

No results posted yet for this study

Summary

Twenty patients with multiple actinic keratosis on the face will be enrolled in the study and will be treated with Daylight Photodynamic therapy.

Before and after skin biopsies will be performed, for histological and immunohistochemical analysis.

Conditions

  • Actinic Keratosis

Interventions

DRUG

Methyl Aminolevulinate

Patients will be treated with Daylight Photodynamic therapy, following these steps: 1. mild curettage of the AK lesions 2. application of a chemical sunscreen SPF 30 3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories) 4. exposition to daylight, for 120 minutes 5. cleaning of the face

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Cyro Festa, md · Hospital das Clinicas da USP

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-04-30
Completion
2017-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03013647 on ClinicalTrials.gov